Сегодня проверял рассылки и нашел следующее:
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial) : The Lancet
The Lancet - Early Online Publication, 06/15/2012 Clinical Article
Davalos A et al. – Under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate–to–severe acute ischaemic stroke
Results
2298 patients were enrolled into the study from Nov 26, 2006, to Oct 27, 2011.
37 centres in Spain, 11 in Portugal, and 11 in Germany recruited patients.
Of the 2298 patients who gave informed consent and underwent randomisation, 1148 were assigned to citicoline and 1150 to placebo.
The trial was stopped for futility at the third interim analysis on the basis of complete data from 2078 patients.
The final randomised analysis was based on data for 2298 patients: 1148 in citicoline group and 1150 in placebo group.
Global recovery was similar in both groups (odds ratio 1.03, 95% CI 0.86-1.25; p=0.364).
No significant differences were reported in the safety variables nor in the rate of adverse events.
Честно говоря, даже имея возможность почитать полнотекстовую статью, не стал. Просто купил пивка и выпил. Выпил за правду, за здравый смысл. А то - цераксон, нас всех спасет цераксон. Приезжает Румянцева и поет с трибуны, что цераксон - единственный препарат с доказательной базой, включенный во все (!!!) международные рекомендации.
Слава правде. Спасибо за внимание
|